Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 50Active not recruiting 28Completed 13Not yet recruiting 12Withdrawn 2Terminated 1Suspended 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Advanced Lung Carcinoma 1

Interventions

pembrolizumab 29Carboplatin 15Cisplatin 13Nivolumab 12atezolizumab 10Radiotherapy 10Paclitaxel 10Ipilimumab 10venetoclax 9Pemetrexed 9Docetaxel 9durvalumab 8Gemcitabine 8fludarabine 7Specimen Handling 7Cyclophosphamide 7Bevacizumab 7tislelizumab 6fludarabine phosphate 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6Biopsy 6enzalutamide 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Dexamethasone 5Cytarabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Irinotecan × 90 days × Clear all
NCT04924192 2026-04-13

A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
21 enrolled

Advanced Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡